Advertisement

Related Videos

Opening Session Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jan
14
Today In Oncology
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Nivolumab Plus AVD Reduces Disease Progression Risk in Advanced Classical Hodgkin Lymphoma
WGS-Based Classifier Better Predicts HRD Across Cancer Types
ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo